AUTL — Autolus Therapeutics Ltd

Autolus Therapeutics Ltd (AUTL) is a biotechnology company listed on NASDAQ. It is led by Christian Martin Itin Ph.D., based in The Mediaworks, London, United Kingdom, W12 7FP, with about 647 employees. Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Latest reported AUTL revenue for 2025-09-30 was $21.2M. Net income was -$79.1M. Revenue was up 1.3% from 2025-06-30 to 2025-09-30. AUTL currently screens at market cap $614.8M.

Use this AUTL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AUTL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AUTL SEC filings page. Lician reads the product cache first so this HTML stays unique to Autolus Therapeutics Ltd even when a live quote feed is slow.